Journal of Bioenergetics and Biomembranes

, Volume 42, Issue 3, pp 189–191 | Cite as

Mitochondrial matters in Huntington disease

Article

Abstract

Huntington Disease (HD) is a relatively common inherited neuropathy with characteristic cognitive and behavioral features. HD usually has a late onset and often is not recognized until the third or fourth decades of life. Transmitted as an autosomal dominant trait, HD has become a prototype for understanding a group of neurogenetic disorders. As a class, HD and the others are manifestations of the expansion of a trinucleotide repeat within the gene coding or structural region. In HD expansion of the (CAG)n repeat in the first exon from an average of 18 (normal) to a median of 44 is the underlying molecular biologic change. In affected individuals, the mutant HD protein (Huntingtin, mHtt) thus contains an extended polyglutamine repeat. Clinical and neuropathic changes in the caudate and putamen nuclei occur relatively early with other brain regions being affected later. Mitochondrial structure, altered electron transport and increased brain lactate levels have implicated mitochondria in HD pathophysiology. There is also evidence that reduced transcription of the peroxisome proliferator-activated receptor-γ coactivator (PGC-1α) leads to altered downstream gene regulation. Further evidence for mitochondrial involvement is presented in the following reviews. Clarifying mitochondrial derangements has led to some possibilities for therapeutic intervention.

Keywords

Huntington DNA amplification DNA repeat Movement disorder Mitochondrion Neuropathy Reactive oxygen species PGC-1α 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N (2006) Krane D. Cell 127:59–69CrossRefGoogle Scholar
  2. Gusella JF, Wexler NS, Conneally MM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, Young AB, Shoulson I, Bonilla E, Martin JB (1983) Nature 306:234–238CrossRefGoogle Scholar
  3. Huntington G (1872) Med Surg Reporter (Philadelphia) 26:317Google Scholar
  4. Jin YN, Johnson GVW (2010) J Bioenerg Biomem doi:10.1007/s10863-010-9286-7
  5. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, Squitieri F, Lin B, Bassett A, Almqvist E, Bird TD, Hayden MR (1994) New Engl J Med 330:1401–1406CrossRefGoogle Scholar
  6. Oliveira JMA (2010) J Bioenerg Biomem doi:10.1007/s10863-010-9287-6
  7. Pandey M, Mohanakumar KP, Usha R (2010) J Bioenerg Biomem doi:10.1007/s10863-010-9288-5
  8. Perez-de la Cruz V, Carrillo-Mora P, Santamaria A (2010) J Bioenerg BiomemGoogle Scholar
  9. Subramaniam S, Sixt KM, Barrow R, Snyder SH (2009) Science 324:1327–1330CrossRefGoogle Scholar
  10. The Huntington’s Disease Collaborative Research Group (1993) Cell 72:971–983CrossRefGoogle Scholar
  11. Turner C, Schapira AHV (2010) J Bioenerg Biomem doi:10.1007/s10863-010-9290-y
  12. Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR (2009) Amer J Hum Genet 84:351–366CrossRefGoogle Scholar
  13. Weydt P, Pineda VV, Torrence AE et al (2006) Cell Metab 4:349–362CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Departments of Medicine and Biological ChemistryThe Johns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations